quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:20:09·62d
INSIDERFiling
PTC Therapeutics Inc. logo

CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $511,253 worth of shares (7,371 units at $69.36), decreasing direct ownership by 2% to 387,082 units (SEC Form 4)

PTCT· PTC Therapeutics Inc.
Health Care
Original source

Companies

  • PTCT
    PTC Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 10UpdateRaymond James$108.00
  • Jan 28UpdateBarclays$119.00
  • Dec 1UpdateRBC Capital Mkts$91.00
  • Oct 20UpdateWells Fargo$73.00
  • Jun 17UpdateTruist$80.00
  • May 9UpdateBofA Securities$68.00

Related

  • INSIDER6h
    CHIEF EXECUTIVE OFFICER Klein Matthew B. sold $202,094 worth of shares (2,850 units at $70.91), decreasing direct ownership by 0.72% to 394,070 units (SEC Form 4) to satisfy withholding tax
  • PR1d
    PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
  • SEC3d
    SEC Form DEFA14A filed by PTC Therapeutics Inc.
  • SEC3d
    SEC Form DEF 14A filed by PTC Therapeutics Inc.
  • PR6d
    PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • ANALYST13d
    Raymond James initiated coverage on PTC Therapeutics with a new price target
  • INSIDER15d
    SEC Form 4 filed by Boulding Mark Elliott
  • INSIDER17d
    SEC Form 4 filed by Golden Lee Scott
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022